Snider William 4
4 · HARVARD BIOSCIENCE INC · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Harvard Bioscience (HBIO) Director William Snider Buys Stock
What Happened
William Snider, a director of Harvard Bioscience, bought shares in open-market purchases on March 16 and March 17, 2026. He acquired 12,525 shares on 3/16 at a weighted-average price of $4.99 (prices ranged $4.85–$5.00) for about $62,500, and 8,475 shares on 3/17 at a weighted-average price of $4.85 (prices ranged $4.80–$4.95) for about $41,104 — a total of 21,000 shares costing roughly $103,604. These were purchases (reporting code P), which are generally interpreted as insider buying rather than selling.
Key Details
- Transaction dates and prices:
- 2026-03-16: 12,525 shares @ weighted avg $4.99 (actual prices $4.85–$5.00) — $62,500. (Footnote F1)
- 2026-03-17: 8,475 shares @ weighted avg $4.85 (actual prices $4.80–$4.95) — $41,104. (Footnote F2)
- Total purchased: 21,000 shares for ~ $103,604.
- Holdings noted in filing: Footnotes indicate the reported holdings include the March 16 and March 17 purchases and 11,000 restricted stock units that vest on December 17, 2026 (these RSUs reflect a 10-for-1 reverse split on March 13, 2026). (Footnotes F3, F4, F5)
- Method/code: P = open market or private purchase.
- Filing timeliness: Report filed 2026-03-18 for transactions on 2026-03-16–03-17; this was filed within the normal Form 4 reporting window (timely).
Context
- Purchases by directors can be seen as a positive signal but don’t prove future company performance; the filing is factual and does not state motivation.
- Note the March 13, 2026 10-for-1 reverse split adjusted previously reported RSU counts (110,000 → 11,000).
Insider Transaction Report
Form 4
Snider William
Director
Transactions
- Purchase
Common Stock
[F1][F3][F5]2026-03-16$4.99/sh+12,525$62,500→ 23,525 total - Purchase
Common Stock
[F2][F4][F5]2026-03-17$4.85/sh+8,475$41,104→ 32,000 total
Footnotes (5)
- [F1]The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
- [F2]The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
- [F3]Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026.
- [F4]Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026.
- [F5]On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Signature
/s/ William Snider|2026-03-18